Literature DB >> 21301487

Management of Cushing disease.

Nicholas A Tritos1, Beverly M K Biller, Brooke Swearingen.   

Abstract

Cushing disease is caused by a corticotroph tumor of the pituitary gland. Patients with Cushing disease are usually treated with transsphenoidal surgery, as this approach leads to remission in 70-90% of cases and is associated with low morbidity when performed by experienced pituitary gland surgeons. Nonetheless, among patients in postoperative remission, the risk of recurrence of Cushing disease could reach 20-25% at 10 years after surgery. Patients with persistent or recurrent Cushing disease might, therefore, benefit from a second pituitary operation (which leads to remission in 50-70% of cases), radiation therapy to the pituitary gland or bilateral adrenalectomy. Remission after radiation therapy occurs in ∼85% of patients with Cushing disease after a considerable latency period. Interim medical therapy is generally advisable after patients receive radiation therapy because of the long latency period. Bilateral adrenalectomy might be considered in patients who do not improve following transsphenoidal surgery, particularly patients who are very ill and require rapid control of hypercortisolism, or those wishing to avoid the risk of hypopituitarism associated with radiation therapy. Adrenalectomized patients require lifelong adrenal hormone replacement and are at risk of Nelson syndrome. The development of medical therapies with improved efficacy might influence the management of this challenging condition.

Entities:  

Mesh:

Year:  2011        PMID: 21301487     DOI: 10.1038/nrendo.2011.12

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  121 in total

1.  Heavy-charged-particle radiosurgery of the pituitary gland: clinical results of 840 patients.

Authors:  R P Levy; J I Fabrikant; K A Frankel; M H Phillips; J T Lyman; J H Lawrence; C A Tobias
Journal:  Stereotact Funct Neurosurg       Date:  1991       Impact factor: 1.875

2.  Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease.

Authors:  Jay Jagannathan; Rene Smith; Hetty L DeVroom; Alexander O Vortmeyer; Constantine A Stratakis; Lynnette K Nieman; Edward H Oldfield
Journal:  J Neurosurg       Date:  2009-09       Impact factor: 5.115

3.  Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome.

Authors:  A Tabarin; A Navarranne; J Guérin; J B Corcuff; M Parneix; P Roger
Journal:  Clin Endocrinol (Oxf)       Date:  1991-01       Impact factor: 3.478

4.  The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

Authors:  J Estrada; M Boronat; M Mielgo; R Magallón; I Millan; S Díez; T Lucas; B Barceló
Journal:  N Engl J Med       Date:  1997-01-16       Impact factor: 91.245

5.  Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas.

Authors:  L S Blevins; J H Christy; M Khajavi; G T Tindall
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

6.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

Authors:  G Minniti; D Traish; S Ashley; A Gonsalves; M Brada
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

7.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

8.  Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome.

Authors:  E H Oldfield; J L Doppman; L K Nieman; G P Chrousos; D L Miller; D A Katz; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

9.  Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome.

Authors:  Elena Valassi; Brooke Swearingen; Hang Lee; Lisa B Nachtigall; Daniel A Donoho; Anne Klibanski; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2009-10-22       Impact factor: 5.958

Review 10.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

View more
  54 in total

1.  A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.

Authors:  Mathias Riebold; Christian Kozany; Lee Freiburger; Michael Sattler; Michael Buchfelder; Felix Hausch; Günter K Stalla; Marcelo Paez-Pereda
Journal:  Nat Med       Date:  2015-02-09       Impact factor: 53.440

Review 2.  Update in the medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-08       Impact factor: 3.243

3.  Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; William H Ludlam
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 5.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

6.  The adrenal psoas sign: surgical outcomes following a simple technique to maximize removal of extracortical adrenal tissue during bilateral laparoscopic adrenalectomy.

Authors:  Erin W Gilbert; Vincent L Harrison; Brett C Sheppard
Journal:  Surg Endosc       Date:  2014-04-25       Impact factor: 4.584

7.  Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma.

Authors:  Carmine Antonio Donofrio; Marco Losa; Marco Gemma; Lodoviga Giudice; Lina Raffaella Barzaghi; Pietro Mortini
Journal:  Endocrine       Date:  2016-12-22       Impact factor: 3.633

8.  The anterior skull base nasal inventory (ASK nasal inventory): a clinical tool for evaluating rhinological outcomes after endonasal surgery for pituitary and cranial base lesions.

Authors:  Andrew S Little; Heidi Jahnke; Peter Nakaji; John Milligan; Kristina Chapple; William L White
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

9.  The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.

Authors:  Chiara Simeoli; Renata Simona Auriemma; Fabio Tortora; Monica De Leo; Davide Iacuaniello; Alessia Cozzolino; Maria Cristina De Martino; Claudia Pivonello; Ciro Gabriele Mainolfi; Riccardo Rossi; Sossio Cirillo; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2015-03-06       Impact factor: 3.633

Review 10.  Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas.

Authors:  Ricardo J Komotar; Robert M Starke; Daniel M S Raper; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.